On October 21, 2020 Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, reported that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio’s UniDabs, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy (Press release, TeneoBio, OCT 21, 2020, View Source;utm_medium=rss&utm_campaign=arsenalbio [SID1234568789]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement ArsenalBio will have commercial rights to UniDabs against therapy-guiding antigens for one of its proprietary immune cell therapy programs. Teneobio will receive an upfront payment, potential clinical and regulatory approval milestones as well as royalties on commercial sales world-wide.

Omid Vafa, CBO of Teneobio, said, "We are excited that ArsenalBio selected UniDabs as part of its efforts to advance immune cell therapies targeting solid tumors. We believe our UniDab platform for targeted cellular therapies offers unique advantages to support the work underway by the ArsenalBio team." Ken Drazan, CEO of ArsenalBio said, "We continue to make notable progress in our pipeline toward addressing the unmet need and suffering of patients with cancer by developing and advancing a new paradigm of human immune cell therapy design, manufacture, and clinical assessment. The UniDab platform will help contribute to this important work on behalf of patients."